Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Progression‐free survival · women with advanced EOC after PDS

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 1.88 [1.63, 2.16]
10 studies · 6596 participants
Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Progression‐free survival · women with advanced EOC after primary IDS

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 322 participants
Very low